Cyclosporine
Peptide targets ABCB1, ABCC2, CYP3A4, IL2, TGFB1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Ikervis | — | 2015-03-19 | europa.eu ↗ |
| Approved | US (FDA) | SANDIMMUNE | — | 1983-11-14 | fda.gov ↗ |
Trials 386 · started per year
Also used as a comparator or background therapy in 511 trials
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-02-03 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease viatris.com ↗ |
| 2020-01-27 | Incyte Corporation | Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine incyte.com ↗ |
Evidence & citations 78 cited values
Every value below carries the sentence it was read from. 941 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclosporine | “A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE®...” NCT01692834 ↗611“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “Healthy adult subjects will receive an IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and coadministration of cyclosporine at 2 hours...” NCT04542252 ↗ “Oral calcineurin inhibitors (tacrolimus 0.075 mg/kg/day in two divided doses, or cyclosporine 2-5 mg/kg/day in two divided doses) administered in combination with standard...” NCT07406932 ↗ “The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface...” NCT06624384 ↗ “Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target...” NCT00706680 ↗ “Topical Cyclosporine 0.05% (Restasis®) is an anti-inflammatory drug which is the most recommended treatment option for patients with moderate-severe DES who failed conservative...” NCT03403023 ↗ “When a donor organ becomes available for transplant, the patient will receive three anti-rejection drugs-cyclosporine, mycophenolate mofetil and prednisone-to prevent organ rejection.” NCT00009009 ↗ “This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).” NCT00048152 ↗ “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ “The introduction of cyclosporine (CsA) into clinical practice resulted in improvements in acute renal allograft rejection rate and graft survival in renal transplant patients.” NCT01990118 ↗ “Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)” NCT01950819 ↗ “Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL.” NCT00854139 ↗ “CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study” NCT06676696 ↗ “Cyclosporine is understood to be an immunomodulatory drug with anti-inflammatory properties, as well as having other actions relevant to managing dry eye disease” NCT03865888 ↗ “available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.” NCT05322148 ↗ “To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED.” PMID 38451509 ↗ Apr 2024 “Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate” NCT01749111 ↗ “Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis” NCT01751126 ↗ “Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough.” NCT01921218 ↗ “relative colonic mucosal concentrations of cyclosporine capsules (CyCol®) compared to intravenous cyclosporine in healthy male volunteers.” NCT02130414 ↗ “In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease” NCT00145587 ↗ “One promising drug candidate is cyclosporine, a polypeptide traditionally used to achieve immunosuppression in transplant recipients.” PMID 37561274 ↗ Aug 2023 “maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice.” NCT01014234 ↗ “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration” NCT02904772 ↗ “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “Patients were randomized to receive either oral methotrexate (15 mg/wk) or cyclosporine (2.5 mg/kg/d) for 8 weeks.” PMID 28967549 ↗ Sep 2017 “All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose.” NCT04342988 ↗ “patients received either an IV bolus injection of 2.0 mg/kg cyclosporine (Sandimmune, Novartis) or placebo.” PMID 25948727 ↗ May 2015 “prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus” NCT00214279 ↗ “Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day” NCT03025698 ↗ “In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.” NCT00186823 ↗ “the government pay a huge amount of money for subsiding the imported cyclosporine in the form of Neoral.” NCT00656695 ↗ “Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.” PMID 20092592 ↗ Dec 2009 “cyclosporine and mycophenolate mofetil prior to the infusion of mobilized peripheral blood stem cells” NCT00325741 ↗ “0.1% tacrolimus (FK-506) ophthalmic ointment with 2% cyclosporine eye drops in the treatment of VKC.” NCT01068054 ↗ “Cyclosporine, a potent inhibitor of the opening of the mitochondrial permeability transition pore” PMID 25050491 ↗ Aug 2014 “Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.” NCT01998633 ↗ “Subject will also be given cyclosporine (Neoral®) therapy for approximately 2 weeks (10-20 days).” NCT00579592 ↗ “Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper” NCT01565616 ↗ “Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.” NCT02004067 ↗ “For patients with pure red cell aplasia (PRCA), cyclosporine (CsA) is the first line therapy.” PMID 32030447 ↗ Feb 2020 “Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816 ↗ “Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL” NCT00864227 ↗ “Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.” NCT01597778 ↗ “include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin” NCT05149365 ↗ “Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression” NCT00966836 ↗ “Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)” NCT01547143 ↗ “low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)]” NCT01023542 ↗ “Tacrolimus or cyclosporine: dosed according to trough levels per standard of care” NCT01053221 ↗ “Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop.” NCT00849888 ↗ “0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days” NCT03597139 ↗ “INTERVENTIONS: Cyclosporine solution vs vehicle administered 2 times per day.” PMID 37022717 ↗ May 2023 “calcineurin inhibitor (tacrolimus or cyclosporine) immunosuppression therapy” NCT01837043 ↗ “cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml)” NCT02392780 ↗ “Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.” NCT00377962 ↗ “Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID.” NCT03828019 ↗ “Cyclosporine before PCI in Patients with Acute Myocardial Infarction.” PMID 26321103 ↗ Aug 2015 “TJCS Eye Drops 0.05%(Cyclosporine ophthalmic nano-emulsion) group” NCT02461719 ↗ “Horse Antithymocyte Globulin, Cyclosporine, Promacta, Eltrombopag” NCT01623167 ↗ “OTX-CSI (Cyclosporine Ophthalmic Insert) for Intracanalicular Use” NCT04362670 ↗ “Cyclosporine will be administered daily at a dosage of 3-5mg/kg.” NCT05975996 ↗ “Solution of Cyclosporine (high dose) administered during 28 days” NCT01120132 ↗ “Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L).” NCT07010237 ↗ “Cyclosporine will be administered daily at a dosage of 3-5mg/kg” NCT06695741 ↗ “cyclosporine 0.1% dissolved in perfluorobutylpentane (Vevye®)” NCT07368595 ↗ “GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3” NCT00745420 ↗ “Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)” NCT01050855 ↗ “GVHD prophylaxis consisted of cyclosporine and Methotrexate.” NCT00152139 ↗ “All patients received cyclosporine 0.1% ophthalmic solution” PMID 38771801 ↗ May 2024 “Cyclosporine will be given orally at a dose of 10 mg/Kg/day” NCT01817322 ↗ “May be cyclosporine, mycophenolate mofetil, or tacrolimus” NCT00135694 ↗ “The target serum level for cyclosporine is 120-200 ng/mL.” NCT01106833 ↗ “Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day” NCT05245604 ↗ “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ “cyclosporine in combination with Avatrombopag to treat” NCT05433922 ↗ “• Calcineurin inhibitor (cyclosporine or tacrolimus)” NCT06821542 ↗ “• Calcineurin inhibitor (cyclosporine or tacrolimus)” NCT07124078 ↗ “Day -3: Begin Tacrolimus or cyclosporine Begin MMF” NCT00920972 ↗ “Atypical subjects given Cyclosporine (Csa) pre-tx.” NCT00579709 ↗ “Restasis® (cyclosporine ophthalmic emulsion 0.05%)” NCT02028312 ↗ “Cyclosporine (Neoral) starting dose 3mg/kg PO BID” NCT00983645 ↗ “p-ALG combined with cyclosporine and Romiplostim” NCT06613880 ↗ “Cyclosporine 3 mg/kg orally in two divided doses” NCT05571332 ↗ “Rituximab combined with or without cyclosporine” NCT05782933 ↗ “Cyclosporine will be started at 200 mg po BID” NCT00282412 ↗ “HU00701(Cyclosporine 0.01% + 3% trehalose)” NCT02917512 ↗ “Cyclosporine 5 mg/Kg/day in 2 oral doses” NCT00323960 ↗ “Cyclosporine 0.02% with Trehalose 3%” NCT04384991 ↗ “Drug: Cyclosporine NOVA22007 0.05%” NCT00328653 ↗ “Cyclosporine 0.02%, trehalose 3%” NCT03461575 ↗ “cyclosporine/MMF starting Day +4” NCT07570745 ↗ “400 mg oral dose of cyclosporine” NCT01437384 ↗ “Cyclosporine 0.02%, trehalose 3%” NCT05743764 ↗ “Cyclosporine (Gengraf)” NCT01936519 ↗ “Cyclosporine (Cyclo)” NCT07381556 ↗ “Cyclosporine (CsA)” NCT07548671 ↗ “Drug: Cyclosporine” NCT00806598 ↗ “Oral Cyclosporine” NCT03801746 ↗ “Cyclosporine” NCT01374750 ↗ “Cyclosporine” NCT00355862 ↗ |
| Known as | aurosporine (cyclosporine 2%) | “aurosporine (cyclosporine 2%)” NCT02206789 ↗ |
| Known as | CEQUA | “CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.” NCT04835623 ↗ |
| Known as | CequaTM | “CequaTM (Cyclosporine 0.09%) ophthalmic solution” NCT04357795 ↗ |
| Known as | CicloMulsion (ready-to-use lipid emulsion of Cyclosporine A) | “CicloMulsion® (ready-to-use lipid emulsion of Cyclosporine A)” NCT01692834 ↗ |
| Known as | ciclosporin | “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗42“A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate...” NCT01033305 ↗ “prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial” PMID 26645190 ↗ Nov 2015 “Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion” NCT01825044 ↗ “Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)” NCT00919815 ↗ “3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)” NCT04144413 ↗ “Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months” NCT01530555 ↗ “Effect of Ciclosporin Eyedrops on Sjögren Syndrome” NCT04597762 ↗ “IKERVIS® (1mg/mL ciclosporin) eye drops” NCT04492878 ↗ “Ciclosporin (e.g. Immunosporin®)” NCT02779114 ↗ |
| Known as | ciclosporin A | “The purpose of this work is to compare the two modalities currently accepted for the treatment of the disease, but in a prophylactic way; topical ciclosporin A against topical...” NCT06348602 ↗9“MATERIALS AND METHODS: Open label, proof of concept, pilot study of 48 weeks therapy with the calcineurin antagonist, ciclosporin A (CsA), in seven patients with 'early' (<two...” PMID 22720101 ↗ Jun 2012 “guideline recommended ciclosporin A (CsA) + anti-thymocyte immunoglobulin (ATG) + thrombopoietin receptor agonists (TPO-RA) as the first-line therapy.” NCT05996393 ↗ “Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal” NCT01002339 ↗ “ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF)” NCT04203108 ↗ “using once-daily ciclosporin A (CsA) 0.1% cationic emulsion (CE).” PMID 42283972 ↗ Jun 2026 |
| Known as | Ciclosporin, CsA | “Ciclosporin, CsA” NCT02617667 ↗ |
| Known as | Ciclosporine (CSA) | “Ciclosporine (CSA)” NCT04523129 ↗ |
| Known as | Ciclosporine A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00456235 ↗ |
| Known as | Ciclosprin A | “Drug: Ciclosprin A” NCT01527240 ↗ |
| Known as | CIS | “The nebulizer generates a mist of cyclosporine inhalation solution (CIS), which is then breathed in through a mouthpiece.” NCT01287078 ↗3“Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer.” NCT00633373 ↗ “Cyclosporine Inhalation Solution (CIS)” NCT00755781 ↗ “Cyclosporine Inhalation Solution (CIS)” NCT00938236 ↗ |
| Known as | CPS | “A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS)” NCT00002790 ↗ |
| Known as | CSA | “The aim of this study was to compare the long-term safety and efficacy of immunosuppressive regimens consisting of cyclosporine (CsA) plus mycophenolate mofetil (MMF) or...” PMID 19744223 ↗ Sep 2009119“MATERIALS AND METHODS: Open label, proof of concept, pilot study of 48 weeks therapy with the calcineurin antagonist, ciclosporin A (CsA), in seven patients with 'early' (<two...” PMID 22720101 ↗ Jun 2012 “Clinical trials have shown that approximately 75-80% of patients who are treated with immunosuppressive drugs, especially the combination of antithymocyte globulin (ATG) and...” NCT00005935 ↗ “Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1%...” NCT00328653 ↗ “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either...” NCT06658002 ↗ “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗ “Patients who were newly diagnosed with non-transfusion-dependent non-severe AA (NTD-NSAA) were randomly assigned to receive either cyclosporine (CsA) combined with luspatercept...” PMID 42057135 ↗ Apr 2026 “A total of 50 participants were randomly assigned to either the CsA group (n = 25, cyclosporine A twice a day and hyaluronic acid twice daily) or the control group (n = 25,...” NCT06936462 ↗ “Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe...” NCT01231841 ↗ “Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily...” PMID 36450107 ↗ Nov 2022 “Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level:...” NCT02864706 ↗ “This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral...” NCT03209219 ↗ “The purpose of this study is to determine the safety and effectiveness of low doses of cyclosporine (CsA) in patients with early HIV infection and to evaluate its effect on the...” NCT00000880 ↗ “In a preclinical model of catecholamine-driven TTS, cyclosporine A (CsA) bolus therapy significantly improved outcome, likely mediated via suppression of calcineurin-driven...” PMID 40268179 ↗ Apr 2025 “The introduction of cyclosporine (CsA) into clinical practice resulted in improvements in acute renal allograft rejection rate and graft survival in renal transplant patients.” NCT01990118 ↗ “The incidence of NODAT is higher with tacrolimus (Tac) compared with cyclosporine (CsA); however, the effects of switching from Tac to CsA in NODAT have not been studied well.” PMID 26036543 ↗ May 2015 “Long-term triple immunosuppressive therapy with cyclosporine (CsA), mycophenolate mofetil (MMF) and prednisolone may be excessively powerful for many transplant recipients.” PMID 23351013 ↗ Jan 2013 “The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)” NCT06898853 ↗ “We report the results of a prospective, randomized study that compared the effectiveness of prednisone or cyclosporine (CSA) as adjuncts to PEX in the treatment of iTTP.” PMID 29296854 ↗ Oct 2017 “This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)” NCT04237987 ↗ “Group C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year.” PMID 14742989 ↗ Jan 2004 “In earlier clinical protocols we treated SAA with cyclosporine A (CSA) (86-H-0007), antithymocyte globulin (ATG) (87-H-0124), and combined ATG and CSA (90-H-0146).” NCT00001964 ↗ “Experimental studies have shown that cyclosporin A (CsA) administered prior to reperfusion binds to cyclophilin D and blocks the opening of mPTP after reperfusion.” NCT02876250 ↗ “This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease.” NCT00974142 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “The calcineurin inhibitors (CNIs) cyclosporine (CsA) and tacrolimus (Tac) are implicated in post-transplant complications such as cardiovascular morbidity.” PMID 23190385 ↗ Nov 2012 “INTRODUCTION: To compare the efficacy of combination therapy using 0.05% cyclosporine A (CsA) and absorbable punctal plugs with that of CsA monotherapy” PMID 41567664 ↗ Jan 2026 “guideline recommended ciclosporin A (CsA) + anti-thymocyte immunoglobulin (ATG) + thrombopoietin receptor agonists (TPO-RA) as the first-line therapy.” NCT05996393 ↗ “Cyclosporine (CsA) absorption varies early after transplantation and can be accurately assessed by the area under the absorption curve (AUC).” PMID 19716045 ↗ Sep 2009 “Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years.” NCT01995331 ↗ “Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation” NCT00139009 ↗ “ciclosporine A (CsA) can also inhibit the opening of a mitochondrial mega-channel called the permeability transition pore (mPTP).” NCT00403728 ↗ “151 incident kidney transplant recipients received cyclosporine (CsA), mycophenolic acid (MPA), and steroids during three months” PMID 33277746 ↗ Dec 2020 “Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus.” PMID 10221490 ↗ Apr 1999 “To evaluate the short-term efficacy of cyclosporine A (CsA)-0.1% cationic emulsion (CE) in patients with dry eye disease (DED)” PMID 38446281 ↗ Mar 2024 “cyclosporine A (CSA) IV continuously over 24 hours or orally every 12 hours on days -1 to 60 followed by a taper until day 100” NCT00619645 ↗ “Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production.” NCT05353101 ↗ “Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL.” NCT00719849 ↗ “Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal” NCT01002339 ↗ “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA.” NCT04692376 ↗ “subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune followed by CsA dose reduction” NCT00257387 ↗ “maintenance immunosuppressive treatment with low-dose cyclosporine (CsA) plus low-dose mycophenolate mofetil (MMF).” NCT00752479 ↗ “Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and action of T cells.” PMID 20735287 ↗ Oct 2010 “cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA.” NCT04743739 ↗ “The initial target trough levels were 100-200 ng/ml for cyclosporine (CSA) and 4-8 ng/mL for tacrolimus (TAC).” PMID 19670189 ↗ Jun 2009 “Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults.” NCT04878770 ↗ “Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination.” PMID 24983307 ↗ Jan 2015 “Oral Cyclosporin A (CsA) has been shown in several human trials to be effective in treating chronic uveitis.” NCT00001737 ↗ “These reperfusion's injuries can be reduced by injection of cyclosporin A (CsA) at the time of reperfusion.” NCT01901471 ↗ “Standard treatment for SAA involves injections of antithymocyte globulin (ATG) plus cyclosporine (CsA).” NCT01193283 ↗ “Other studies have shown Cyclosporine A (CsA) may block the progression of advanced breast cancer.” NCT00983424 ↗ “conventional treatment with Cyclosporine A (CsA), Mycophenolate mofetil (MMF), and corticosteroids” NCT01266148 ↗ “Cyclosporine A (CsA) could partially reduce ischaemia/reperfusion-induced injury in isolated heart” PMID 12411407 ↗ Nov 2002 “to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora” NCT04637633 ↗ “Inhaled cyclosporine (CsA) is being investigated as a prophylaxis for lung transplant rejection.” PMID 23668548 ↗ May 2013 “Systemic immunosuppressants such as cyclosporine (CsA) can be effective for treating ocular GVHD” NCT00102583 ↗ “include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin” NCT05149365 ↗ “The incidence of GVHD was dependent on the duration of cyclosporin A (CsA) immunosuppression.” PMID 9849691 ↗ Nov 1998 “Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.” NCT00005937 ↗ “For patients with pure red cell aplasia (PRCA), cyclosporine (CsA) is the first line therapy.” PMID 32030447 ↗ Feb 2020 “Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d.” NCT03689465 ↗ “Few controlled trials have used topical Cyclosporine A (CsA) for the treatment of VKC.” NCT00426023 ↗ “oral cyclosporine A (CsA)(serum levels 250-350 mcg/L) for the first 8 weeks of HAART.” NCT00979706 ↗ “Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.” NCT03710044 ↗ “combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28” PMID 17563739 ↗ Jun 2007 “MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A” NCT00323960 ↗ “Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).” NCT05936086 ↗ “Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks.” NCT06147375 ↗ “usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA)” NCT00944749 ↗ “Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months” NCT01530555 ↗ “ALG/CsA(Cyclosporine) and herombopag and moderate-dose cyclophosphamide” NCT05975996 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF)” NCT07562568 ↗ “standard horse antithymocyte globulin (h-ATG) and cyclosporine (CsA)” PMID 19181786 ↗ Jan 2009 “daily topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)” PMID 36856978 ↗ Mar 2023 “Cyclosporine A (CsA) monotherapy often yields suboptimal responses” PMID 41489450 ↗ Jan 2026 “Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)” NCT00004208 ↗ “topical 0.5% cyclosporine A (CSA) and fluorometholone (FML)” PMID 33201059 ↗ Jun 2021 “Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)” NCT03035422 ↗ “Atypical subjects given Cyclosporine (Csa) pre-tx.” NCT00579709 ↗ “Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)” NCT03079089 ↗ “Cyclosporine A (CSA) is a calcineurin inhibitor” PMID 35536669 ↗ Jun 2022 “CSA (cyclosporine A) will be given from day 21.” NCT03456817 ↗ “topical cyclosporine A (Cs-A) 0.05% eye drops” PMID 41784713 ↗ Mar 2026 “Group A: CsA + Azathioprine(1 to 2 mg/kg/day)” NCT00461825 ↗ “cyclosporine (CsA) IV or orally twice daily” NCT00550992 ↗ “Cyclosporine A (CsA 3 mg/kg) start day +5” NCT03295058 ↗ “Cyclosporine (CSA) and methotrexate (MTX)” NCT00741455 ↗ “Reduction of cyclosporine A (CSA)-dosing” NCT00663455 ↗ “Tacrolimus (TCL) or Cyclosporine A (CsA)” NCT04705584 ↗ “cyclosporine (CsA, Sandimmune, Neoral)” NCT00428064 ↗ “Cyclosporine A (CsA) 2% eye drops” NCT01211327 ↗ “Cyclosporin A(CsA)+glucocorticoid” NCT02370550 ↗ “0.05% CsA: 0.05% cyclosporin A” NCT02147509 ↗ “6 months CsA (Cyclosporine)” NCT00260689 ↗ “Drug: Cyclosporine A (CsA)” NCT00251004 ↗ “Drug: Cyclosporin (CSA)” NCT07375654 ↗ “Cyclosporine A (CsA)” NCT00571662 ↗ “Cyclosporine A (CsA)” NCT02226068 ↗ “Cyclosporine A (CsA)” NCT07366801 ↗ “cyclosporine A (CsA)” NCT02091414 ↗ “Cyclosporine A (CsA)” NCT07345000 ↗ “Cyclosporin A (CsA)” NCT06802055 ↗ “Cyclosporin A (CSA)” NCT02472054 ↗ “Cyclosporine (CsA)” NCT07558434 ↗ “Cyclosporine (CsA)” NCT07548671 ↗ “Cyclosporine (CsA)” NCT00256750 ↗ “Cyclosporine (CsA)” NCT07653581 ↗ “Cyclosporine (CsA)” NCT06790095 ↗ “Cyclosporine (CsA)” NCT00948727 ↗ “Cyclosporine (CsA)” NCT07523009 ↗ “Cyclosporin (CSA)” NCT07381556 ↗ “Cyclosporin (CSA)” NCT07522996 ↗ |
| Known as | CsA (Cyclosporin) | “CsA (Cyclosporin)” NCT00001880 ↗ |
| Known as | CsA-CE | “PURPOSE: This study evaluates the efficacy and tolerability of cyclosporine A cationic emulsion (CsA-CE) in patients ≥4 years of age with moderate-to-severe vernal...” PMID 37872059 ↗ Oct 2023 |
| Known as | CSP | “This is a prospective, randomized, placebo-controlled study about Cyclosporine A (CSP) and traumatic brain injury (TBI).” NCT02496975 ↗2“cyclosporine (CSP) and mycophenolate mofetil (MMF)” NCT01251575 ↗ “cyclosporine (CSP) at initial dose of 6.25 mg/kg” NCT00325741 ↗ |
| Known as | CyA | “This study aims to investigate the efficacy and safety of low-dose cyclosporine A (CyA) in patients with primary Sjögren's syndrome (pSS) and articular involvement.” PMID 27470087 ↗ Jul 20162“The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN.” PMID 21626222 ↗ May 2011 “Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day” NCT00976300 ↗ |
| Known as | CyclASol | “PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to...” PMID 30703441 ↗ Jan 20191“OBJECTIVE: To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared...” PMID 37022717 ↗ May 2023 |
| Known as | cyclo | “Although high doses of cyclosporin (cyclo) inhibits the development of type 1 diabetes mellitus” NCT00905073 ↗ |
| Known as | cyclosporin | “Previous studies in humans have shown that, taken by mouth, the drug cyclosporin is effective in treating chronic uveitis.” NCT00001737 ↗46“cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days)” NCT02834468 ↗ “MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol” NCT00764725 ↗ “Cyclosporin will begin on day -2 (IV or oral) for at least 180 days.” NCT01015742 ↗ “Cyclosporin is administered at a dose of 3-5mg/kg per day.” NCT06254560 ↗ “one will take a cyclosporin 0.1% eye drop emulsion” NCT00001731 ↗ “Tacrolimus, Cyclosporin, NeoOral, Prograf” NCT01455649 ↗ “Cyclosporin for inhalation twice daily” NCT01334892 ↗ “Restasis (topical cyclosporin)” NCT00348335 ↗ “topical cyclosporin eyedrops” NCT04597762 ↗ “0.05% cyclosporin eye drop” NCT00705510 ↗ “Drug: Cyclosporin (CSA)” NCT07375654 ↗ |
| Known as | Cyclosporin 0.05% emulsion (Restasis) | “Cyclosporin 0.05% emulsion (Restasis)” NCT02199964 ↗ |
| Known as | Cyclosporin A | “Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide,...” NCT01033656 ↗58“This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral...” NCT03209219 ↗ “All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .” NCT04451239 ↗ “This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)” NCT04237987 ↗ “Experimental studies have shown that cyclosporin A (CsA) administered prior to reperfusion binds to cyclophilin D and blocks the opening of mPTP after reperfusion.” NCT02876250 ↗ “The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye” NCT02199964 ↗ “Cyclosporin A is an immunomodulator that specifically inhibits T lymphocytes by blocking the expression of the interleukin-2 receptor.” NCT00987467 ↗ “These reperfusion's injuries can be reduced by injection of cyclosporin A (CsA) at the time of reperfusion.” NCT01901471 ↗ “cyclosporin A 0.05% cyclosporine A eye drops were administered three times daily to both eyes.” NCT07171710 ↗ “Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.” NCT06944132 ↗ “Cyclosporin A Combined to Intravenous Thrombolysis. Multicenter Randomized Placebo-controlled” NCT01527240 ↗ “The incidence of GVHD was dependent on the duration of cyclosporin A (CsA) immunosuppression.” PMID 9849691 ↗ Nov 1998 “Researchers can choose cyclosporin A or tacrolimus according to patient tolerance.” NCT03192657 ↗ “P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused” NCT02144792 ↗ “sulfasalazine plus hydroxychloroquine could be replaced by cyclosporin A” NCT00764725 ↗ “Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv” NCT01087398 ↗ “Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv” NCT01238328 ↗ “Cyclosporin A (Sandimmun Neoral® or similar):” NCT02936505 ↗ “0.05% CsA: 0.05% cyclosporin A” NCT02147509 ↗ |
| Known as | Cyclosporin A (CsA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00332839 ↗ |
| Known as | Cyclosporin: NEORAL | “Cyclosporin: NEORAL” NCT00922129 ↗ |
| Known as | Cyclosporine (CSP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00568633 ↗ |
| Known as | cyclosporine (Neoral, Sandimmune and other trade names) | “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ |
| Known as | cyclosporine A | “A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic...” NCT02404025 ↗143“The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1%...” NCT00328653 ↗ “This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant...” NCT01650545 ↗ “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗ “Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily...” PMID 36450107 ↗ Nov 2022 “The purpose of this work was to evaluate the effect of loteprednol etabonate (LE) before the initiation of topical cyclosporine A (tCsA) therapy in patients with...” PMID 25083776 ↗ Sep 2014 “The most accepted pharmacological modality is the topical application of cyclosporine A; on the other hand, tacrolimus has shown greater immunosuppressive power when used in...” NCT06348602 ↗ “Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.” NCT05660785 ↗ “OBJECTIVE: To assess patients' experiences with topical cyclosporine A (tCSA) 0.05% ophthalmic emulsion (Restasis) to treat keratoconjunctivitis sicca (KCS) in a real-world setting.” PMID 16004673 ↗ Jul 2005 “Comparative Evaluation of 0.05% Cyclosporine A Plus Absorbable Punctal Plugs Versus 0.05% Cyclosporine A Monotherapy in Sjögren's Syndrome-Associated Dry Eye: A Paired-Eye Study” NCT07171710 ↗ “Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily.” NCT01598987 ↗ “Topical Cyclosporine A is a fungal metabolite that reduces ocular inflammation by inhibiting Th2 lymphocyte proliferation and histamine release from mast cells and basophils.” NCT04705584 ↗ “Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)” NCT01380535 ↗ “0.05% cyclosporine A (Cyporin N Eye Drops, Taejoon Pharm, Republic of Korea) and 0.15% hyaluronic acid (New Hyaluni Eye Drops, Taejoon Pharm) were used in this study.” NCT06936462 ↗ “Group C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year.” PMID 14742989 ↗ Jan 2004 “This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease.” NCT00974142 ↗ “Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes” NCT00704275 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT07562568 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms” NCT00405457 ↗ “Cyclosporine A is a peptide produced by a fungus that has been used systemically for decades for its potent immunomodulatory effects.” NCT06392438 ↗ “Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes” NCT01028443 ↗ “cyclosporine A (CSA) IV continuously over 24 hours or orally every 12 hours on days -1 to 60 followed by a taper until day 100” NCT00619645 ↗ “Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production.” NCT05353101 ↗ “To evaluate the short-term efficacy of cyclosporine A (CsA)-0.1% cationic emulsion (CE) in patients with dry eye disease (DED)” PMID 38446281 ↗ Mar 2024 “Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL.” NCT00719849 ↗ “Cyclosporine A will be started on day 1 of cycle 2 (day 29) at a dose of 5 mg/kg per day given orally in 2 divided doses.” NCT00840827 ↗ “Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and action of T cells.” PMID 20735287 ↗ Oct 2010 “Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination.” PMID 24983307 ↗ Jan 2015 “A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL” NCT00002759 ↗ “Cyclosporine A has long been known to suppress T cell responses by inhibiting the production of IL-2” PMID 30880061 ↗ Mar 2019 “conventional treatment with Cyclosporine A (CsA), Mycophenolate mofetil (MMF), and corticosteroids” NCT01266148 ↗ “Cyclosporine A (CsA) could partially reduce ischaemia/reperfusion-induced injury in isolated heart” PMID 12411407 ↗ Nov 2002 “Other studies have shown Cyclosporine A (CsA) may block the progression of advanced breast cancer.” NCT00983424 ↗ “to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora” NCT04637633 ↗ “Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)” NCT00148252 ↗ “LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.” NCT00447642 ↗ “combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28” PMID 17563739 ↗ Jun 2007 “Topical 0.05% cyclosporine A and 0.1% sodium hyaluronate were used for 3 months.” PMID 38247010 ↗ Jan 2024 “A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease:” PMID 34481407 ↗ Oct 2021 “Cyclosporine A: initiated on Day -9 through Day +180, tapered gradually” NCT07440654 ↗ “associated with 8 weeks of cyclosporine A (0.3-0.6 mg/kg twice daily)” PMID 27999018 ↗ Mar 2017 “daily topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)” PMID 36856978 ↗ Mar 2023 “Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)” NCT00004208 ↗ “cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2” NCT01028092 ↗ “Cyclosporine A or Tacrolimus 3 mg/kg/day from -1 to 120” NCT05515029 ↗ “cyclosporine-A alone in case of an HLA-sibling donor” NCT02876679 ↗ “Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)” NCT03035422 ↗ “Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)” NCT03079089 ↗ “Cyclosporine A (CSA) is a calcineurin inhibitor” PMID 35536669 ↗ Jun 2022 “CSA (cyclosporine A) will be given from day 21.” NCT03456817 ↗ “Cyclosporine A (CsA 3 mg/kg) start day +5” NCT03295058 ↗ “Cyclosporine A solution in vehicle” NCT04523129 ↗ “Cyclosporine A solution in vehicle” NCT04523142 ↗ “cyclosporine A 5 mg per kg IV” NCT00063817 ↗ “Restasis (Cyclosporine A)” NCT00399061 ↗ “Cyclosporine A Solution” NCT02113293 ↗ “cyclosporine A” NCT00061360 ↗ “cyclosporine A” NCT01659606 ↗ |
| Known as | cyclosporine A (CsA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328727 ↗ |
| Known as | Cyclosporine Capsule | “Drug: Cyclosporine Capsule” NCT05696977 ↗ |
| Known as | Cyclosporine Eye Drops (Restasis) | “Cyclosporine Eye Drops (Restasis)” NCT02461719 ↗ |
| Known as | Cyclosporine Eye Drops(CYPORIN N) | “Cyclosporine Eye Drops(CYPORIN N)” NCT02461719 ↗ |
| Known as | Cyclosporine microemulsion | “Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as...” NCT00149890 ↗ |
| Known as | CycloSPORINE Ophthalmic Suspension | “Drug: CycloSPORINE Ophthalmic Suspension” NCT04705584 ↗ |
| Known as | Cyclosporine(CsA) | “Cyclosporine(CsA)” NCT05571332 ↗ |
| Known as | Cyclosporine/Neoral/Sandimmune/Gengraf | “Cyclosporine/Neoral®/Sandimmune®/Gengraf®” NCT00905515 ↗ |
| Known as | Cyclosporine: Cipol | “Cyclosporine: Cipol” NCT01547143 ↗ |
| Known as | Cyclosporins | “Drug: Cyclosporins” NCT00282412 ↗ |
| Known as | CyCol | “relative colonic mucosal concentrations of cyclosporine capsules (CyCol®) compared to intravenous cyclosporine in healthy male volunteers.” NCT02130414 ↗ |
| Known as | CyIS | “Aerosol Cyclosporine (CyIS)” NCT00783107 ↗ |
| Known as | Cylosporine A | “It is suspected that Cylosporine A (Sandimmun, TM) is less diabetogenic than Tacrolimus (Prograf, TM).” NCT01268995 ↗ |
| Known as | Cyporin N Eye Drops | “0.05% cyclosporine A (Cyporin N Eye Drops, Taejoon Pharm, Republic of Korea) and 0.15% hyaluronic acid (New Hyaluni Eye Drops, Taejoon Pharm) were used in this study.” NCT06936462 ↗ |
| Known as | CYSP | “Determine the maximum tolerated dose of irinotecan (CPT-11) when infused weekly with cyclosporine (CYSP) in patients with solid tumors or lymphoma refractory to standard therapy.” NCT00002759 ↗1“addition of cyclosporine (CYSP) to mitoxantrone (DHAD) and etoposide (VP-16)” NCT00002688 ↗ |
| Known as | Formulation 01B | “Ciclosporin 0.5% (Formulation 01B)” NCT00578370 ↗ |
| Known as | Formulation 02B | “Ciclosporin 1.5% (Formulation 02B)” NCT00578370 ↗ |
| Known as | Gengraf | “Gengraf a microemulsion formulation of CsA though granted an AB-rated equivalent to Neoral, because of concerns over the use of generic drugs in transplantation, we undertook...” NCT01990118 ↗1“Cyclosporine (Gengraf )” NCT00944749 ↗ |
| Known as | Gengraf (cyclosporin) | “Gengraf (cyclosporin)” NCT01492894 ↗ |
| Known as | HU007 | “Purpose: To compare the efficacy and safety of HU00701 (0.01% cyclosporin A + 3% trehalose), HU007 (0.02% cyclosporin A + 3% trehalose) (all w/v), and placebo” PMID 33449860 ↗ Jan 2021 |
| Known as | HU00701 | “Purpose: To compare the efficacy and safety of HU00701 (0.01% cyclosporin A + 3% trehalose), HU007 (0.02% cyclosporin A + 3% trehalose) (all w/v), and placebo” PMID 33449860 ↗ Jan 2021 |
| Known as | Ikervis | “The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)” NCT06898853 ↗2“IKERVIS® (1mg/mL ciclosporin) eye drops” NCT04492878 ↗ “Cyclosporine 0.1% (Ikervis®) eye drop” NCT04775303 ↗ |
| Known as | Immunosporin | “Ciclosporin (e.g. Immunosporin®)” NCT02779114 ↗ |
| Known as | L-CsA | “This is a randomized single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) in the treatment of chronic rejection in...” NCT01650545 ↗1“L-CsA” NCT04039347 ↗ |
| Known as | Liposomal Cyclosporine A | “Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy” NCT03656926 ↗1“Liposomal Cyclosporine A 5 mg” NCT04039347 ↗ |
| Known as | Neoral | “Group C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year.” PMID 14742989 ↗ Jan 200422“All these patients, receiving treatment with oral cyclosporine (Neoral®, Novartis) at 2.5 mg/kg/day, were examined at three-month intervals for a year.” PMID 29454364 ↗ Feb 2018 “Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio.” NCT00000936 ↗ “cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2” NCT01028092 ↗ “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ “Neoral® capsule containing 25mg or 100mg cyclosporine” NCT01990118 ↗ “cyclosporine (CsA, Sandimmune, Neoral)” NCT00428064 ↗ “Sandimmun (Neoral) dose plus cellcept” NCT04906304 ↗ “Neoral® (Cyclosporine)” NCT00518375 ↗ “Cyclosporine (Neoral)” NCT00419926 ↗ “Cyclosporine(Neoral®)” NCT01817322 ↗ “cyclosporin (Neoral)” NCT00938860 ↗ “Neoral/Prograf” NCT00267189 ↗ |
| Known as | Neoral (cyclosporin) | “Neoral (cyclosporin)” NCT01492894 ↗ |
| Known as | NeoralÒ | “The patients will be given immunosuppressant treatment based on rabbit anti-T lymphocyte serum, CellCeptÒ and NeoralÒ cyclosporin.” NCT00200551 ↗ |
| Known as | NeuroSTAT | “Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion” NCT01825044 ↗ |
| Known as | NOVA22007 | “Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis” NCT01751126 ↗ |
| Known as | OTX-CSI | “a single dose of OTX-CSI, a sustained release cyclosporine drug product” NCT04362670 ↗ |
| Known as | PT-CsA | “CRS is usually limited after the administration of post-transplant cyclosporine (PT-CsA) administered on days +3 and +4” NCT04781803 ↗ |
| Known as | Restasis | “The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface...” NCT06624384 ↗29“The purpose of this study is to evaluate the efficacy of 0.05% cyclosporin ophthalmic emulsion (Restasis) in patients with Stevens-Johnson syndrome that have dry eyes by...” NCT01488396 ↗ “OBJECTIVE: To assess patients' experiences with topical cyclosporine A (tCSA) 0.05% ophthalmic emulsion (Restasis) to treat keratoconjunctivitis sicca (KCS) in a real-world setting.” PMID 16004673 ↗ Jul 2005 “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ “Cyclosporin A (Restasis®, Allergan, Irvine, CA) has been shown to significantly reduce the number of activated T-lymphocytes within the conjunctiva” NCT00565669 ↗ “The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye” NCT02199964 ↗ “Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.” NCT00755040 ↗ “All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose” NCT04637633 ↗ “Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes” NCT02461719 ↗ “active comparator (cyclosporine ophthalmic emulsion, 0.05% [Restasis, Allergan Inc., Irvine, CA])” PMID 22607938 ↗ May 2012 “Restasis® is also known as cyclosporine ophthalmic emulsion 0.05% (cyclosporine eye drops).” NCT00824811 ↗ “0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days” NCT03597139 ↗ “topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan)” NCT00349440 ↗ “Restasis® (cyclosporine ophthalmic emulsion 0.05%)” NCT02028312 ↗ “0.05% cyclosporine emulsion (generic Restasis®)” NCT07368595 ↗ “0.05% cyclosporin (Restasis®, Allergan Inc)” NCT05771012 ↗ “Restasis (topical cyclosporin)” NCT00348335 ↗ “Restasis (cyclosporine 0.05%)” NCT01804361 ↗ “Restasis(Cyclosporine 0.05%)” NCT02917512 ↗ “Restasis (Cyclosporine A)” NCT00399061 ↗ |
| Known as | RESTASIS (cyclosporine ophthalmic emulsion) 0.05% | “RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%” NCT03597139 ↗ |
| Known as | Restasis eye drop | “Restasis eye drop 0.05% (Cyclosporine)” NCT04384991 ↗ |
| Known as | Sandimmun | “Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil” NCT04376970 ↗2“It is suspected that Cylosporine A (Sandimmun, TM) is less diabetogenic than Tacrolimus (Prograf, TM).” NCT01268995 ↗ |
| Known as | Sandimmun i.v. | “Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days.” NCT00332462 ↗ |
| Known as | Sandimmun Neoral | “All participants received cyclosporine (Sandimmun Neoral) monitored by C0 and blood was collected for analysis of C2 retrospectively.” PMID 19716045 ↗ Sep 20094“Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)” NCT00148252 ↗ “Cyclosporin A (Sandimmun Neoral® or similar):” NCT02936505 ↗ “Cyclosporine (Sandimmun Neoral)” NCT00488436 ↗ |
| Known as | Sandimmun Optoral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00514514 ↗ |
| Known as | Sandimmune | “patients received either an IV bolus injection of 2.0 mg/kg cyclosporine (Sandimmune, Novartis) or placebo.” PMID 25948727 ↗ May 20154“Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio.” NCT00000936 ↗ “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ “2.5 mg of cyclosporine (Sandimmune, Novartis)” NCT00990795 ↗ “cyclosporine (CsA, Sandimmune, Neoral)” NCT00428064 ↗ |
| Known as | SCAI-001 | “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ |
| Known as | SHR8028 | “To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED.” PMID 38451509 ↗ Apr 2024 |
| Known as | ST-0529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03844932 ↗ |
| Known as | TJO-087 | “Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily...” PMID 36450107 ↗ Nov 2022 |
| Known as | Vevye | “Vevye (cyclosporine ophthalmic solution) is administered twice daily (BID) in both eyes for the treatment of dry eye disease.” NCT07553455 ↗3“cyclosporine 0.1% dissolved in perfluorobutylpentane (Vevye®)” NCT07368595 ↗ “cyclosporine 0.1% ophthalmic solution (US brand name VEVYE)” PMID 38771801 ↗ May 2024 |
| Action | Inhibit | “CsA is capable of decreasing T cell activation, which in turn may decrease HIV replication.” NCT00000880 ↗ |
| Modality | Other / unclassified | “immunosuppressive calcineurin inhibitor (CNI)” NCT00296296 ↗ |
| Route | Oral | “Administered orally as either sandimmune or neoral at a dose determined by weight.” NCT00000936 ↗ |
| Target | ABCB1 | “The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.” PMID 23953030 ↗ Aug 2013 |
| Target | ABCC2 | “The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.” PMID 23953030 ↗ Aug 2013 |